Frontier Pharma - Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation by Researchmoz

Albany, NY -- (SBWIRE) -- 04/22/2014 -- GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected to enter the market over the next few years. Despite this, the current developmental pipeline is highly innovative beyond these me-too products and incremental innovations and promises a number of first-in-class products across all stages. These new developments are driven by improvements in the understanding of signaling pathways and underlying disease mechanisms of Rheumatoid Arthritis (RA). These highly innovative products are expected to increase the diversity of available products, in terms of mechanism of action over the coming decade and are likely to have a significant impact on the dynamics of the clinical and commercial landscape.